Skip to content

Platelet Indices in Patients Undergoing Primary PCI and Its Prognostic Value

Platelet Indices in Patients Undergoing Primary Percutaneous Coronary Intervention :Its Relation to the Severity of Coronary Artery Disease and Its Prognostic Value

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04290949
Enrollment
100
Registered
2020-03-02
Start date
2020-02-20
Completion date
2021-12-01
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

To assess the platelet indices in patients undergoing primary percutaneous coronary intervention and its relation to the severity of coronary artery disease and short term clinical outcomes

Detailed description

Acute coronary syndromes (ACS) is a type of acute coronary artery disease (CAD), It is a highly prevalent group of emergency diseases, associated with high morbidity and mortality (1) ACS include ST- elevation Myocardial Infarction (STEMI), non ST-Elevation Myocardial Infarction (NSTEMI) and Unstable Angina (UA) (2). ACS characterized by plaque rupture and acute thrombosis formation in the coronary arteries (3) platelet morphology and function have vital roles in the pathogenesis of many diseases related to coagulation, thrombosis, inflammation, and endothelial dysfunction (4) Platelets play a crucial role in thrombotic episodes, its activation is acritical factor in the creation and evolution of atherothrombosis. (5) Not only platelets are essential for the thrombotic vascular occlusion at the ruptured atherosclerotic plaque but also they contribute to the obstruction and impairment of coronary micro circulation (6). Risk stratification plays a crucial role in the management of patients with ACS (7). Patients estimated to be at higher risk may be managed with earlier and more aggressive treatment, whereas those with lower risk may be managed with less intensive treatment (8). Many biomarkers have been evaluated, and various scores have been created for risk stratification of ACS patients (9) Mean platelet volume (MPV) has been proposed as a primary marker for platelet activation, as larger sized platelets have been associated with higher pro-thrombotic risk, and its measurement is easy and time effective (10-14) * So It may elevate in patients with ACS and its role, It could be a useful bio marker of risk of stratification (15) * Platelet Distribution Width (PDW) measured on admission is a cheap and generally available biomarker which allows for predicting the development of heart failure in patients with ACS after PCI (16) showed that an increased level of PDW was related to the severity of CAD in patients with ACS (17). Numerous studies support the association of Mean platelet volume (MPV) with adverse cardiac outcomes as restenosis stent thrombosis in patients with ACS (19-24) al.2011

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult patients (age ≥ 18 years) that presented with acute ST elevation myocardial infarction

Exclusion criteria

1. Cardiomyopathy, 2. Previous revascularization procedure 3. Any history of bleeding diathesis

Design outcomes

Primary

MeasureTime frameDescription
the severity of coronary artery disease and short term clinical outcomesfollow up patients 6 monthesPlatelet indices as mean Platelet Volume (MPV)in femtoliter , platelet distribution width (PDW) (FL)% and (PCT)% May be larger and could be a risk of Stratification in patients undergoing primary percutaneous coronary intervention

Contacts

Primary ContactIshraq Hassan, Physician
Ishraqhosny@gmail.com+201065967424
Backup ContactAhmed Thabet, Lecturer
drahmedfarag2005@yahoo.com+201061461306

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026